Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 06, 2005. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan due to a fund movement on June 02, 2005:
- Prior Holding: 18,301,017 ADRs
- Current Holding: 18,260,572 ADRs
- Average Price: $49.40
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No specific guidance, outlook, or risk factors regarding the company's operations are provided in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the reporting date.
- Confirm the specific impact of the fund movement on the holdings of directors Dr. J P Garnier and Dr. T Yamada.
- Check subsequent filings for any further changes in director interests or fund movements.